ERLOSHIL 150MG TABLETS
| Parameter | Details |
|---|---|
| Product Name | Erloshil Tablet |
| Strength | 150 mg |
| Active Ingredient | Erlotinib |
| Drug Class | EGFR Tyrosine Kinase Inhibitor |
| Form | Tablet |
| Route of Administration | Oral |
| Packaging | Blister pack / Bottle (as per manufacturer) |
| Storage Condition | Store below 30°C in a dry place |
| Prescription Required | Yes |
| Usage | Treatment of lung and pancreatic cancer |
ERLOSHIL 150MG TABLETS
Erloshil 150mg Tablets contains erlotinib, a prescription EGFR tyrosine kinase inhibitor (TKI) used for targeted treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. By blocking the signaling pathways that drive cancer cell growth, Erloshil helps slow tumor progression and supports effective disease management under oncologist supervision.
Erloshil works as a precision oral therapy by selectively targeting epidermal growth factor receptors (EGFR) in tumor cells. This mechanism helps inhibit cancer cell proliferation and spread, making it a valuable option for patients with EGFR-positive NSCLC or advanced pancreatic cancer who require targeted chemotherapy.
Administered orally, the Erloshil 150 mg Tablet offers the convenience of outpatient cancer treatment while maintaining clinical effectiveness. It is prescribed as part of long-term oncology protocols and must be taken strictly as prescribed by the oncologist to ensure optimal outcomes and patient safety.
Product Features
- Oral targeted anticancer tablet
- Contains Erlotinib 150 mg
- EGFR tyrosine kinase inhibitor
- Used in NSCLC and pancreatic cancer
- High-specificity targeted therapy
- Convenient once-daily oral dosage
- Manufactured under GMP-compliant standards
- Prescription-required oncology medicine
How It Helps
- Blocks EGFR signals to inhibit cancer cell growth
- Slows tumor progression in NSCLC and pancreatic cancer
- Provides high-specificity targeted oral therapy
- Supports effective cancer treatment under an oncologist’s supervision
Reviews
There are no reviews yet.